Keros Therapeutics, Inc.
KROS
$14.41
$0.251.77%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 6,844.31% | 684.02% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 6,844.31% | 684.02% | |||
| Cost of Revenue | 138.05% | -360.03% | |||
| Gross Profit | 24.04% | 368.32% | |||
| SG&A Expenses | -1.58% | 8.60% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.17% | -4.66% | |||
| Operating Income | 385.50% | 9.21% | |||
| Income Before Tax | 446.62% | 13.65% | |||
| Income Tax Expenses | 3,247.67% | -- | |||
| Earnings from Continuing Operations | 422.54% | 13.09% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 422.54% | 13.09% | |||
| EBIT | 385.50% | 9.21% | |||
| EBITDA | 387.94% | 9.29% | |||
| EPS Basic | 420.78% | 19.01% | |||
| Normalized Basic EPS | 444.71% | 19.53% | |||
| EPS Diluted | 417.27% | 59.52% | |||
| Normalized Diluted EPS | 440.83% | 19.53% | |||
| Average Basic Shares Outstanding | 0.55% | 7.31% | |||
| Average Diluted Shares Outstanding | 1.69% | 7.31% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||